首页> 美国卫生研究院文献>British Journal of Cancer >Prognostic significance of the sequential detection of circulating melanoma cells by RT–PCR in high-risk melanoma patients receiving adjuvant interferon
【2h】

Prognostic significance of the sequential detection of circulating melanoma cells by RT–PCR in high-risk melanoma patients receiving adjuvant interferon

机译:RT-PCR顺序检测循环黑色素瘤细胞对高危黑色素瘤患者接受辅助干扰素的预后意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The purpose of this study was to address the prognostic significance of circulating melanoma cells by reverse transcriptase-polymerase chain reaction in the peripheral blood of stage IIB and III melanoma patients on high-dose adjuvant interferon at multiple sequential time points from initiation of treatment. Tyrosinase mRNA in peripheral blood from these patients was assayed by reverse transcriptase polymerase chain reaction prior to initiation of adjuvant interferon, at completion of 1 month of intravenous interferon and at 3 monthly intervals until progression. Four hundred and eighteen blood samples from 60 melanoma patients were analysed. The median follow-up time calculated from the time of inclusion in the study was 23 months (range 2–38 months). Tyrosinase mRNA in blood was detected in 42 (70%) of 60 patients: 16 (76%) of 21 stage IIB patients and 26 (66%) of 39 stage III patients. The presence of tyrosinase mRNA in blood was correlated with a shorter disease-free survival (P : 0.03) and in multivariante analysis was an indepent prognostic factor for relapse. Patients who seroconverted to a negative reverse-transcriptase-polymerase chain reaction after induction treatment had a significantly lower probability of recurrence. The presence of circulating melanoma cells is a marker of a high relapse risk and shorter disease-free survival whether detected postoperatively or during follow-up. Tyrosinase mRNA amplification by reverse-transcriptase-polymerase chain reaction may be a useful tool for monitoring the efficacy of adjuvant treatment in stage IIB and III melanoma patients.British Journal of Cancer (2002) >87, 181–186. doi: © 2002
机译:本研究旨在通过逆转录酶-聚合酶链反应在治疗开始后多个连续时间点对IIB和III期黑素瘤患者外周血进行大剂量辅助干扰素治疗循环黑素瘤细胞的预后意义。在开始辅助干扰素治疗之前,静脉干扰素治疗1个月完成时和间隔3个月直至进展之前,通过逆转录酶聚合酶链反应分析这些患者外周血中的酪氨酸酶mRNA。分析了60名黑色素瘤患者的418份血液样本。从纳入研究时间算起的中位随访时间为23个月(范围2–38个月)。在60例患者中有42例(70%)检测到血液中的酪氨酸酶mRNA:21例IIB期患者中16例(76%)和39例III期患者中26例(66%)。血液中酪氨酸酶mRNA的存在与较短的无病生存期相关(P:0.03),在多变量分析中,酪氨酸酶mRNA是复发的独立预后因素。诱导治疗后血清转化为逆转录酶-聚合酶链反应阴性的患者复发的可能性大大降低。循环黑素瘤细胞的存在是高复发风险和较短的无病生存期的标志,无论是在术后还是在随访期间发现。通过逆转录酶-聚合酶链反应扩增酪氨酸酶mRNA可能是监测IIB和III期黑色素瘤患者辅助治疗疗效的有用工具。英国癌症杂志(2002年)> 87 ,第181-186页。 doi:©2002

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号